Literature DB >> 26668077

Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.

L Piccolo1,2, M Woodhall3, G Tackley1, M Juryńczyk1, Y Kong4, J Domingos1,5, R Gore1, A Vincent3, P Waters3, M I Leite1, J Palace6.   

Abstract

Severe, recurrent or bilateral optic neuritis (ON) often falls within the neuromyelitis optica spectrum disorders (NMOSD), but the diagnosis can be particularly challenging and has important treatment implications. We report the features, course and outcomes of patients presenting with atypical ON when isolated at onset. We retrospectively analyzed 69 sequential patients referred to a single UK NMO center with isolated ON at onset. Aquaporin-4 antibody (AQP4-Ab) assessment was performed in all patients and IgG1 myelin-oligodenrocyte glycoprotein (MOG-Ab) in AQP4-Ab(neg) patients. 37 AQP4-Ab positive (AQP4-Ab(pos)) and 32 AQP4-Ab negative (AQP4-Ab(neg)) patients (8 with MOG-Ab) were identified. The AQP4-Ab(neg) group included heterogeneous diagnoses: multiple sclerosis (MS), NMO, relapsing isolated ON (RION), monophasic isolated ON and relapsing acute disseminated encephalomyelitis (ADEM)-like syndromes. Compared to AQP4-Ab(neg) patients, AQP4-Ab(pos) patients had a worse residual visual outcome from first attack (median VFSS 4 vs. 0, p = 0.010) and at last assessment (median VFSS 5 versus 2, p = 0.005). However, AQP4-Ab(neg) patients with RION also had poor visual outcome. Up to 35% of AQP4-Ab(neg) patients developed a LETM and two developed low positivity for AQP4-Ab over time. Eight AQP4-Ab(neg) patients (25%) were MOG-Ab positive, covering a range of phenotypes excluding MS; the first ON attack was often bilateral and most had relapsing disease with a poor final visual outcome [VFSS 4, range (0-6)]. In conlcusion, AQP4-Ab positivity is confirmed as a predictor of poor visual outcome but AQP4-Ab(neg) RION also had a poor visual outcome. Of those without AQP4-Ab, 25% had MOG-Ab and another 25% developed MS; thus, MOG-Ab is associated with AQP4-Ab(neg) non-MS ON.

Entities:  

Keywords:  AQP4-Ab; MOG-Ab; Neuromyelitis optica; Optic neuritis; Visual loss

Mesh:

Substances:

Year:  2015        PMID: 26668077     DOI: 10.1007/s00415-015-7983-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Authors:  P J Waters; A McKeon; M I Leite; S Rajasekharan; V A Lennon; A Villalobos; J Palace; J N Mandrekar; A Vincent; A Bar-Or; S J Pittock
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

2.  Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.

Authors:  Joanna Kitley; Maria Isabel Leite; Wilhelm Küker; Gerardine Quaghebeur; Jithin George; Patrick Waters; Mark Woodhall; Angela Vincent; Jacqueline Palace
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

3.  Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

Authors:  Sean J Pittock; Brian G Weinshenker; Claudia F Lucchinetti; Dean M Wingerchuk; John R Corboy; Vanda A Lennon
Journal:  Arch Neurol       Date:  2006-07

4.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

5.  Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.

Authors:  Kevin C O'Connor; Katherine A McLaughlin; Philip L De Jager; Tanuja Chitnis; Estelle Bettelli; Chenqi Xu; William H Robinson; Sunil V Cherry; Amit Bar-Or; Brenda Banwell; Hikoaki Fukaura; Toshiyuki Fukazawa; Silvia Tenembaum; Susan J Wong; Norma P Tavakoli; Zhannat Idrissova; Vissia Viglietta; Kevin Rostasy; Daniela Pohl; Russell C Dale; Mark Freedman; Lawrence Steinman; Guy J Buckle; Vijay K Kuchroo; David A Hafler; Kai W Wucherpfennig
Journal:  Nat Med       Date:  2007-01-12       Impact factor: 53.440

6.  Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.

Authors:  Joanna Kitley; Patrick Waters; Mark Woodhall; M Isabel Leite; Andrew Murchison; Jithin George; Wilhelm Küker; Saleel Chandratre; Angela Vincent; Jacqueline Palace
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

7.  Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.

Authors:  Joanna Kitley; Mark Woodhall; Patrick Waters; M Isabel Leite; Emma Devenney; John Craig; Jacqueline Palace; Angela Vincent
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

8.  Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease.

Authors:  Fabienne Brilot; Russell C Dale; Rebecca C Selter; Verena Grummel; Sudhakar Reddy Kalluri; Muhammad Aslam; Verena Busch; Dun Zhou; Sabine Cepok; Bernhard Hemmer
Journal:  Ann Neurol       Date:  2009-12       Impact factor: 10.422

9.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

10.  Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial.

Authors: 
Journal:  Ophthalmology       Date:  2007-11-05       Impact factor: 12.079

View more
  14 in total

1.  MOG antibody-related disorders: common features and uncommon presentations.

Authors:  Álvaro Cobo-Calvo; Anne Ruiz; Hyacintha D'Indy; Anne-Lise Poulat; Maryline Carneiro; Nicolas Philippe; Françoise Durand-Dubief; Kumaran Deiva; Sandra Vukusic; Vincent Desportes; Romain Marignier
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

Review 2.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

3.  Clinical characteristics of optic neuritis in Hong Kong population: 10-year review.

Authors:  Bonnie Nga Kwan Choy; Alex Lap Ki Ng; Jimmy Shiu Ming Lai
Journal:  Int Ophthalmol       Date:  2017-03-13       Impact factor: 2.031

Review 4.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

5.  Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China.

Authors:  Guixian Zhao; Qian Chen; Yongheng Huang; Zhenxin Li; Xinghuai Sun; Ping Lu; S Yan; Min Wang; Guohong Tian
Journal:  J Neurol       Date:  2017-11-03       Impact factor: 4.849

6.  Acute Management of Optic Neuritis: An Evolving Paradigm.

Authors:  Lindsay Horton; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2018-09       Impact factor: 3.042

Review 7.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Authors:  Markus Reindl; Patrick Waters
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

8.  Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.

Authors:  Sara Mariotto; Sergio Ferrari; Salvatore Monaco; Maria Donata Benedetti; Kathrin Schanda; Daniela Alberti; Alessia Farinazzo; Ruggero Capra; Chiara Mancinelli; Nicola De Rossi; Roberto Bombardi; Luigi Zuliani; Marco Zoccarato; Raffaella Tanel; Adriana Bonora; Marco Turatti; Massimiliano Calabrese; Alberto Polo; Antonino Pavone; Luisa Grazian; GianPietro Sechi; Elia Sechi; Daniele Urso; Rachele Delogu; Francesco Janes; Luciano Deotto; Morena Cadaldini; Maria Rachele Bianchi; Gaetano Cantalupo; Markus Reindl; Alberto Gajofatto
Journal:  J Neurol       Date:  2017-10-23       Impact factor: 4.849

Review 9.  Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.

Authors:  Patrick Peschl; Monika Bradl; Romana Höftberger; Thomas Berger; Markus Reindl
Journal:  Front Immunol       Date:  2017-05-08       Impact factor: 7.561

10.  Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype.

Authors:  Laura Navarro Cantó; Sara Carratalá Boscá; Carmen Alcalá Vicente; Sara Gil-Perontín; Francisco Pérez-Miralles; Jessica Castillo Villalba; Laura Cubas Nuñez; Bonaventura Casanova Estruch
Journal:  Front Neurol       Date:  2019-11-01       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.